USA USA: 1-631-626-9181 Europe Europe: 44-208-144-6005  

Search

Tissue samples, tissue arrays, cells, microorganisms, probes and services for your research.

Web Search    Google
Featured Services
Ordering Information

Payment methods we support:
✭ Invoice / Purchase Order
✭ Credit card


Pseudotype-Based Neutralization Assay

Inquiry

The outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of vaccines capable of inducing neutralizing antibodies (NAbs) is a key goal to control the global COVID-19 pandemic. However, the novel coronavirus SARS-CoV-2 is highly contagious and highly pathogenic, presenting tremendous difficulties for neutralization evaluation of drug candidates and vaccines.

To address this issue, Creative Bioarray offers Pseudotype-Based Neutralization Assay service to evaluate neutralizing antibodies against SARS-CoV-2. Pseudotype-based neutralization assay employs pseudovirus as an alternative to wild-type SARS-CoV-2. The infectivity of pseudotyped SARS-CoV-2 is limited to a single round of replication. Thus, pseudovirus can be handled in BSL-2 facilities. Pseudotype-based method enables safe and rapid neutralization analysis to study functional antibody response against coronaviruses.

Competition of NAbs with ACE2 for binding to the spike protein of SARS-CoV-2.Fig.1 Competition of NAbs with ACE2 for binding to the spike protein of SARS-CoV-2.

Pseudotype-Based Neutralization Assay

Creative Bioarray uses hACE2 stable cell lines as in vitro models for neutralization assay. As the fluorescence or luciferase level is correlated to the extent of pseudovirus infection, neutralizing potency of test substance can be quantified by measuring the reduction of signals in NAb-treated cells compared to non-treated control. This method is preferable than the conventional method due to its safety, superior sensitivity, reproductivity and high throughput capacity.

Related Products for Neutralization Assay

  • Pseudoviruses

Compared with infectious SARS-CoV-2, pseudovirus is a biologically safe, reliable and effective tool for COVID-19 studies. Pseudovirus can be processed with safety, has extensive host ranges, and exhibits high competency of transfection in cells.

Cat #Product Name
CoV-001SARS-CoV-2 S Pseudotyped GFP Lentivirus
CoV-002SARS-CoV-2 S Pseudotyped Luciferase Lentivirus
CoV-009SARS-CoV-2 S Pseudotyped mCherry Lentivirus
CoV-010VSV-SARS-CoV2 S-deltaG-mCherry
CoV-011AAV-SARS-CoV2 S-GFP
CoV-003SARS-CoV-2 E Pseudovirus
CoV-004SARS-CoV-2 M Pseudovirus
CoV-005SARS-CoV-2 N Pseudovirus
CoV-006SARS-CoV-2 abEN Pseudovirus
CoV-007SARS-CoV-2 abMEN Pseudovirus
CoV-008SARS-CoV-2 abSMEN Pseudovirus
  • hACE2 Stable Cell Line

Creative Bioarray offers various stable cell lines overexpressing human ACE2 genes, which have been validated and can be used for in vitro neutralization assays to screen potential NAbs or drug candidates.

Cat #Product NameDescription
CSC-RO0292hACE2 Stable Cell Line - HEK293Human Embryonic Kidney-Derived Cell Line
CSC-RO0641hACE2 Stable Cell Line - HEK293THuman Embryonic Kidney-Derived Cell Line
CSC-RO0289hACE2 Stable Cell Line - HeLaHuman Cervical Cancer Cell-Derived Cell Line
CSC-RO0293hACE2 Stable Cell Line - CHO-K1Chinese Hamster Ovary-Derived Cell Line
CSC-RO0291hACE2 Stable Cell Line - NIH-3T3Mouse Embryonic Fibroblast-Derived Cell Line
CSC-RO0642hACE2 Stable Cell Line - A549Human Lung Carcinoma-Derived Cell Line
CSC-RO0290hACE2 Stable Cell Line - COS7Monkey Kidney Fibroblast-Derived Cell Line
CSC-RO0645hACE2 Stable Cell Line - VeroMonkey Kidney Cell Line
CSC-RO0646hACE3 Stable Cell Line - BHKHamster Kidney Fibroblast Cell Line

Feel free to contact us

If you are interested in our pseudotype-based neutralization service or related product, contact us today to get more info. Our scientists would be happy to answer your questions. Please let us know your research interests. We are looking forward to working with you. Contact us today at or 1-631-626-9181 for support.

References

  1. Zhou G, et al., Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020 Mar 15;16(10):1718-1723.
  2. Shanmugaraj B, et al., Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 38.1 (2020): 10-18.
  3. Wang, Chunyan, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications 11.1 (2020): 1-6.
Customer Support & Price Inquiry
Please input "bioarray" as verification code.
CONTACT US USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-626-9181
Fax: 1-631-614-7828
Email: 

Europe
Tel: 44-208-144-6005
Email: